GlassScriptPhysician profile
Samina Fazal
NPI 1992790620
$3,688.43
in general payments reported to CMS, 2019-2025
29 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $210 · 2021: $303 · 2022: $683 · 2023: $707 · 2024: $726 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895 · Education: $5.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.76 |
| Education | $5.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,176.81 | 2019-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $369.18 | 2020-2025 | Envarsus |
| Vifor Pharma, INC. | $301.22 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $206.89 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $182.31 | 2023-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $164.84 | 2019-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $163.70 | 2020-2025 | Ultomiris |
| Cormedix INC. | $146.96 | 2024-2025 | Defencath, Defencath |
| Otsuka America Pharmaceutical, INC. | $132.90 | 2019-2025 | Jynarque |
| Nxstage Medical, INC. | $117.69 | 2019-2025 | Nxstage Cartridge Express, Nxstage System One |
| Janssen Pharmaceuticals, INC | $117.06 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.78 | 2022-2024 | |
| Amgen INC. | $95.21 | 2024-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $53.56 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| La Jolla Pharmaceutical Company | $36.50 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $35.46 | 2022-2023 | Lupkynis |
| Chiesi USA, INC. | $34.94 | 2019-2025 | Elfabrio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.56 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.89 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.34 | 2019 | |
| Novo Nordisk INC | $23.47 | 2024 | Ozempic |
| Amicus Therapeutics, INC. | $23.32 | 2022 | |
| Calliditas Therapeutics US INC. | $20.23 | 2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.61 | 2021 | |
| Akebia Therapeutics INC | $19.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.98 | 2024 | Jardiance |
| Shire North American Group INC | $17.31 | 2019 | |
| Scpharmaceuticals INC. | $16.10 | 2025 | |
| Fresenius USA Marketing, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samina Fazal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.